Get started
Work

O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC

Year: 2019
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.jtho.2019.09.090
Authors: S. Gadgeel, M.C. Garassino, E. Esteban, G. Speranza, E. Felip, M.J. Hochmair, S. Powell, S.Y.-S. Cheng, H.G. Bischoff, N. Peled, R. Hui, M. Reck, T. Kurata, E.B. Garon, M. Boyer, J. Yang, M.C. Pietanza, D. Rodríguez-Abreu
Institutions: University of Michigan, The Barbara Ann Karmanos Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Universitario Central de Asturias, Université de Sherbrooke, Vall d'Hebron Institute of Oncology, Ludwig Boltzmann Institute for Lung Health, Sanford Health, Sunnybrook Health Science Centre, Tel Aviv University, Soroka Medical Center, The University of Sydney, Westmead Hospital, German Center for Lung Research, Kansai Medical University, Kansai Medical University Hospital, University of California, Los Angeles, Chris O’Brien Lifehouse, Merck & Co., Inc., Rahway, NJ, USA (United States), Universidad de Las Palmas de Gran Canaria, Hospital Universitario Insular de Gran Canaria
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2984418866
FWCI: 0.329
Cites:
Cited by: 3
Related to: 10